YEEDOZENCOM Appears at China Focus @ San Francisco 2020
The China Focus @ San Francisco 2020 was solemnly held in San Francisco, the United States on January 12, local time. As the largest China theme docking event in the JP Morgan Conference Week, this conference attracted more than 50 senior executives from well-known Chinese and foreign pharmaceutical companies and investment institutions, roadshows of 40 innovative companies and nearly 700 participants from China, the United States, Europe, Canada, Japan, South Korea and other countries.
As a leading domestic CRO company providing regulatory and clinical services, the YEEDOZENCOM team led by Mr. Dong Lingyun, the General Manager, actively participated in various activities of the conference, and organized the YEEDOZENCOM special session focusing on the reform of the drug registration and regulatory system in China. The guests participating in the special session included Professor Huo Xiumin from Yeehong Business School of Shenyang Pharmaceutical University, Mr. Xiao Zhi, Managing Director of SDIC Innovation Investment Management Co., Ltd., and Mr. Li Zhenyu, Business Development Director of Lunan Pharmaceutical Group Co., Ltd.
Professor Huo Xiumin interpreted the newly revised Pharmaceutical Administration Law in terms of the policies and regulations most concerned by overseas project parties. She said that the reform and continuous improvement of China's drug regulatory system over the past few years obtained significant achievements, solved the backlogs of applications, and greatly improved the efficiency of review and approval by optimizing clinical review and approval process, speeding up the registration and listing process for innovative drugs and clinically urgent drugs.
The guests also had in-depth communication with participants on topics of interest, such as China's newly revised drug listing regulations, Chinese market access and demand, and reached at a good interaction.
About YEEDOZENCOM
YEEDOZENCOM is a leading organization providing drug regulatory service in China. Both the founding team and the current management team of the company have long-term working experience in China’s Center for Drug Evaluation, have deep insights into pharmaceutical policies and regulations, and have an accurate grasp of the new drug review criteria. We will provide the most efficient service to help overseas companies to complete the registration and application of their drugs in China so as to launch in China as soon as possible. In addition, YEEDOZENCOM also provides one-stop services as a clinical CRO. The clinical team can start preparatory work during the IND application process to shorten the time required.
